Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cediranib + whole-brain radiation therapy
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
"R-National Cancer Institute (NCI)-brain metastasis" refers to a therapeutic regimen consisting of the small molecule tyrosine kinase inhibitor cediranib (AZD2171) administered in combination with whole-brain radiation therapy (WBRT). Cediranib acts as a potent inhibitor of vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), as well as platelet-derived growth factor receptors (PDGFR) and c-Kit, thereby exerting anti-angiogenic and anti-tumor effects. This specific combination was evaluated in Phase 1 clinical trials sponsored by the National Cancer Institute (NCI) for the treatment of patients with brain metastases, particularly those originating from non-small cell lung cancer (NSCLC) and other solid tumors. The rationale for the combination is that cediranib may enhance the efficacy of radiation therapy by normalizing tumor vasculature and reducing peritumoral edema, potentially improving local control of metastatic lesions in the brain.
- Other names
- Cediranib maleateAZD2171 + WBRT
02
Targets
PDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on cediranib + whole-brain radiation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cediranib + whole-brain radiation therapy.